Apg7 (13A2) Monoclonal Antibody

Flow cytometric analysis of HeLa cells with Apg7 (13A2) Monoclonal Antibody (bsm-52523R) at 1:50 dilution (red) compared with an unlabeled control (cells without incubation with primary antibody; black).

$Jurkat cell lysate probed with Apg7 (13A2) Monoclonal Antibody (bsm-52523R) at 1:1000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.$

Jurkat cell lysate probed with Apg7 (13A2) Monoclonal Antibody (bsm-52523R) at 1:1000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.

$IF(ICC) staining with Apg7 (13A2) Monoclonal Antibody (bsm-52523R) at 1:100 in HeLa cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with Apg7 (13A2) Monoclonal Antibody (bsm-52523R) at 1:100 in HeLa cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$IF(ICC) staining with Apg7 (13A2) Monoclonal Antibody (bsm-52523R) at 1:100 in HepG2 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with Apg7 (13A2) Monoclonal Antibody (bsm-52523R) at 1:100 in HepG2 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$Paraformaldehyde-fixed and paraffin-embedded Human tonsil tissue incubated with Apg7 (13A2) Monoclonal Antibody (bsm-52523R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human tonsil tissue incubated with Apg7 (13A2) Monoclonal Antibody (bsm-52523R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Human kidney tissue incubated with Apg7 (13A2) Monoclonal Antibody (bsm-52523R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human kidney tissue incubated with Apg7 (13A2) Monoclonal Antibody (bsm-52523R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

Applications

WB
FCM
IHC-P
IF(ICC)
IHC

Reactivity

Human

Overview
Catalog #	bsm-52523R
Product Name	Apg7 (13A2) Monoclonal Antibody
Applications	WB, FCM, IHC-P, IF(ICC), IHC
Reactivity	Human
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	Human Apg7 between 1-200 amino acids
Clonality	Monoclonal
Clone #	13A2
Isotype	IgG
Concentration	1ug/ul
Purification	Purified by Protein A.
Storage Buffer	Aqueous buffered solution containing 1xTBS (pH7.4), 1%BSA, 40%Glycerol and 0.05% Sodium Azide.
Storage Condition	Store at -20°C for 12 months.
Target
Gene ID	10533
Swiss Prot	O95352
Synonyms	Ubiquitin-like modifier-activating enzyme ATG7, ATG12-activating enzyme E1 ATG7, Autophagy-related protein 7, Ubiquitin-activating enzyme E1-like protein, APG7-like, hAGP7, ATG7
Background	E1-like activating enzyme involved in the 2 ubiquitin-like systems required for cytoplasm to vacuole transport (Cvt) and autophagy. Activates ATG12 for its conjugation with ATG5 as well as the ATG8 family proteins for their conjugation with phosphatidylethanolamine. Both systems are needed for the ATG8 association to Cvt vesicles and autophagosomes membranes. Required for autophagic death induced by caspase-8 inhibition. Required for mitophagy which contributes to regulate mitochondrial quantity and quality by eliminating the mitochondria to a basal level to fulfill cellular energy requirements and preventing excess ROS production. Modulates p53/TP53 activity to regulate cell cycle and survival during metabolic stress. Plays also a key role in the maintenance of axonal homeostasis, the prevention of axonal degeneration, the maintenance of hematopoietic stem cells, the formation of Paneth cell granules, as well as in adipose differentiation.
Application Dilution
WB	1:300-5000
FCM	1:20-100
IHC-P	1:200-400
IF(ICC)	1:50-200
IHC

Applications

Reactivity

Search our catalog of hundreds of thousands of products